Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. Fundamental Analysis
Pediatrix Medical Group, Inc. (MD) shows moderate financial fundamentals with a PE ratio of 9.95, profit margin of 9.02%, and ROE of 20.09%. The company generates $1.9B in annual revenue with weak year-over-year growth of -4.92%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 45.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MD's fundamental strength across five key dimensions:
Efficiency Score
WeakMD struggles to generate sufficient returns from assets.
Valuation Score
ExcellentMD trades at attractive valuation levels.
Growth Score
WeakMD faces weak or negative growth trends.
Financial Health Score
ExcellentMD maintains a strong and stable balance sheet.
Profitability Score
ModerateMD maintains healthy but balanced margins.
Key Financial Metrics
Is MD Expensive or Cheap?
P/E Ratio
MD trades at 9.95 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, MD's PEG of 0.02 indicates potential undervaluation.
Price to Book
The market values Pediatrix Medical Group, Inc. at 1.97 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 5.37 times EBITDA. This is generally considered low.
How Well Does MD Make Money?
Net Profit Margin
For every $100 in sales, Pediatrix Medical Group, Inc. keeps $9.02 as profit after all expenses.
Operating Margin
Core operations generate 11.61 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.09 in profit for every $100 of shareholder equity.
ROA
Pediatrix Medical Group, Inc. generates $8.42 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pediatrix Medical Group, Inc. produces operating cash flow of $259.04M, showing steady but balanced cash generation.
Free Cash Flow
Pediatrix Medical Group, Inc. generates strong free cash flow of $237.66M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.86 in free cash annually.
FCF Yield
MD converts 13.81% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
9.95
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.97
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.90
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.72
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.25
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How MD Stacks Against Its Sector Peers
| Metric | MD Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 9.95 | 29.88 | Better (Cheaper) |
| ROE | 20.09% | 682.00% | Weak |
| Net Margin | 9.02% | -46037.00% (disorted) | Weak |
| Debt/Equity | 0.72 | 0.42 | Weak (High Leverage) |
| Current Ratio | 1.25 | 4.49 | Neutral |
| ROA | 8.42% | -16420.00% (disorted) | Weak |
MD outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pediatrix Medical Group, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
10.80%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
120.84%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
32.99%
Industry Style: Defensive, Growth, Innovation
High Growth